about
Economic Theory and Self-Reported Measures of Presenteeism in Musculoskeletal DiseasePsychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomesMultiple adverse pregnancy outcomes before symptom onset are associated with a worse disease outcome in women with recent-onset inflammatory polyarthritisFollowup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo.Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register.The relationship between post-onset pregnancy and functional outcome in women with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis RegisterMortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register.Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts.Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohortsRadiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis.In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register.Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk Arthritis Register.Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis RegisterA good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity.The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial.Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategyUsing epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis.Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritisThe association between low socioeconomic status with high physical limitations and low illness self-perception in patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study.Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register.Tight control in the treatment of rheumatoid arthritis: efficacy and feasibilityThe incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis RegisterPredictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register.Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis.The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritisN-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR)What is the outcome of RA in 2011 and can we predict it?Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literature.Outcomes of early rheumatoid arthritis--the WHO ICF framework.How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.Has the severity of rheumatoid arthritis at presentation diminished over time?Rheumatoid arthritis and work: The impact of rheumatoid arthritis on absenteeism and presenteeism.
P50
Q26741224-843EA7E5-6B62-463D-BBBD-E253531C5030Q26768683-EF2E690B-A4A7-4524-9B85-065390FAA62BQ26824440-F79CDF78-4260-4CC8-8D50-37E6CA381CABQ31038512-C3CD3D60-65A9-4CA3-AF00-D5E11E404BF2Q31043666-E42446FC-D5CC-4AE0-87A0-A94B31CB5CE8Q33692177-16538C70-C3EA-4E47-851D-1DDAD24F7830Q33990812-8D67F109-449E-4B66-8964-DC7DD0C40FEDQ34092449-2463D06D-FEF3-49B1-8D2A-9EAF3A7090F0Q34409733-0D49B3B0-8E5C-4BD5-846A-5D468E416E41Q34481954-DC869E3A-DEF7-49C4-AC16-424818C3832DQ34746646-38D0A350-37C1-46CF-8777-03D16F7A5611Q34758793-C32422DF-A982-447E-97B6-DB7681B2E9F4Q34805081-352979BA-D9BB-47B0-87BF-C7587827D576Q34896346-89859986-38E7-404C-99E1-BD2FFDDA089CQ35082791-EF9260C5-8EB4-4369-9ACE-D05280AC6DB4Q35144251-8CBBD6CC-56A7-484A-B32F-843D021BA18BQ35537108-16170343-3B6C-4617-861A-F90860B5B4A9Q35554643-1BB5239C-C9A0-4ED4-85BC-8BC2B82C8CE4Q35555089-0E209AFC-8675-4658-99D8-413B31D6FD62Q35557805-A271834D-3CE5-479A-BF84-E25529BF447CQ35638133-4E4A4C29-1ADB-49E0-8AF2-D8AB7E56512DQ35754240-A270F50D-4F5C-475C-A38E-01213CDCBB04Q35953401-321F3554-250D-43FF-9EE2-95923EC513A4Q35953478-8B404E20-AA04-41A5-99FB-FC4D3C8E552CQ36204088-63D67019-74C2-47F6-A31B-91E8BB0F19F7Q36382714-334F312D-5A33-4DF2-BB39-117D3D9ABD95Q36532896-0651F081-DFEE-4A69-9358-43FA91247C5FQ36968730-A4383222-9540-4A51-9929-47B2451859A0Q36969898-36ECBE4C-8591-4AC8-95A7-8167CA52B900Q37012704-F64855FE-1BDE-49A5-B172-3C588CC0056AQ37195347-B3CC03B2-FDA2-4D80-9D13-5325CB70E0C8Q37344503-F4BDB6A4-0A40-47CD-945A-5144A6E8D468Q37387224-8400A5FE-535D-4BAC-BEFE-1DE32AD18D42Q37658795-93CC6095-ABB0-40F8-A60F-5C4A4DA9E54DQ37964310-06CD6D88-D7C2-484B-8FBD-9FCCD4170E47Q37977864-5F6F04CB-64EE-447D-877C-D1C75D31642CQ38169362-8767B9C1-B053-442A-9495-B4F1C9C5E92EQ38411038-5E09FA22-7FC9-47C3-A974-C7EC54F64684Q38419984-AC9E13F8-0339-47FF-B21A-E96DA869ADB0Q38649932-770D3752-243D-4B3F-A735-436036E2DCB6
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Suzanne Verstappen
@ast
Suzanne Verstappen
@en
Suzanne Verstappen
@es
Suzanne Verstappen
@nl
Suzanne Verstappen
@sl
type
label
Suzanne Verstappen
@ast
Suzanne Verstappen
@en
Suzanne Verstappen
@es
Suzanne Verstappen
@nl
Suzanne Verstappen
@sl
prefLabel
Suzanne Verstappen
@ast
Suzanne Verstappen
@en
Suzanne Verstappen
@es
Suzanne Verstappen
@nl
Suzanne Verstappen
@sl
P106
P1153
6603191436
P21
P31
P496
0000-0001-6181-0646